Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

The study met its primary endpoint with no procedure or device related serious adverse events reportedRUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GCTK) (“Glucotrack” or the “Company” ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

Glucotrack (GCTK) announced the successful completion of its first in human clinical study, marking a significant milestone in continuous ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

GlucoTrack, Inc. (GCTK) is down by 24.56 percent during Tuesday trading despite announcing the successful completion of a ...

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...

An acute internal jugular, subclavian, or axillary DVT is a relatively ... with an internal jugular vein thrombosis being the most common source. The inconsistent use of anticoagulation therapy ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

Since a TIVAP is set up via the internal jugular vein or the subclavian vein with a tunneled catheter, it can be removed at any time when the treatment is over, serious complications arise, or the ...

The Princess of Wales made just two public appearances in 2024 before declaring she was focusing on staying 'cancer-free'.

A systematic review and meta-analysis found that real-time ultrasound guidance significantly increased the success rate of subclavian vein cannulation and reduced complication rates compared to ...